New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:40 EDTCYTRCytRx reports additional analyses supporting results from Phase 2 trial
CytRx reported positive results from additional statistical analyses that further support the previously announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas. Additional analysis determined hazard ratios for the primary endpoint of progression-free survival by both investigators at study sites and by a blinded radiology review performed at an independent central laboratory. The hazard ratio for investigator-read scans is 0.37, reflecting a 63% reduction in the risk of disease progression; and the hazard ratio for central lab scans is 0.59, reflecting a 41% reduction in the risk of disease progression. Hazard ratios the likelihood that the study endpoint will be reached during a given period are an important measure of the reliability and uniformity of the absolute data for PFS, as presented below. Hazard ratios where the upper limit is less than 1 indicate that there is a significant difference between the two study groups. CytRx also reported that a Kaplan-Meier analysis of the trial results, which describes the time it takes for tumors to progress in individual patients, showed significant improvement in subjects treated with aldoxorubicin versus subjects treated with doxorubicin. CytRx expects to present full study results for this clinical trial at the American Society for Clinical Oncology Meeting in June, 2014 in Chicago, Illinois.
News For CYTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
06:14 EDTCYTRCytRx annouces publication of preclinical glioblastoma data in Neoplasia
Subscribe for More Information
October 20, 2014
06:09 EDTCYTRCytRx announces positive data from Phase 1b/2 study of Aldoxorubicin
Subscribe for More Information
October 17, 2014
09:17 EDTCYTROn The Fly: Pre-market Movers
Subscribe for More Information
06:15 EDTCYTRCytRx aldoxorubicin trial not yet reached enough survival events to report OS
CytRx announced that data regarding the company's Phase 2b global clinical trial of aldoxorubicin for the treatment of first-line soft tissue sarcoma, or STS, will be presented in a moderated paper presentation at the 2014 Connective Tissue Oncology Society Annual Meeting which is being held October 15-18, 2014, in Berlin, Germany. Due to the longer than expected survival of patients in the clinical trial, there have not been a sufficient number of survival events to enable the company to report data on overall survival, or OS, a secondary endpoint of the study.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use